



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 037 607 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
25.02.2004 Bulletin 2004/09

(21) Application number: **98966609.4**

(22) Date of filing: **08.12.1998**

(51) Int Cl.7: **A61K 9/02, A61K 31/44**

(86) International application number:
PCT/EP1998/007946

(87) International publication number:
WO 1999/029299 (17.06.1999 Gazette 1999/24)

(54) **NOVEL SUPPOSITORY FORM COMPRISING AN ACID-LABILE ACTIVE COMPOUND**

NEUE SUPPOSITORIUMSFORM MIT SÄUREEMPFINDLICHE WIRKSTOFFE

NOUVELLE FORME DE SUPPOSITOIRE RENFERMANT UN COMPOSE ACTIF ACIDOLABILE

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **08.12.1997 DE 19754324
20.05.1998 DE 19822549**

(43) Date of publication of application:
27.09.2000 Bulletin 2000/39

(60) Divisional application:
03020043.0 / 1 371 361

(73) Proprietor: **ALTANA Pharma AG
78467 Konstanz (DE)**

(72) Inventors:
• **LINDER, Rudolf
D-78464 Konstanz (DE)**
• **DIETRICH, Rango
D-78465 Konstanz (DE)**

(74) Representative: **Rupp, Herbert, Dr. et al
ALTANA Pharma AG
Byk-Gulden-Strasse 2
78467 Konstanz (DE)**

(56) References cited:
EP-A- 0 645 140 **WO-A-98/52564**

EP 1 037 607 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**Technical field**

[0001] The present invention relates to the field of pharmaceutical technology and describes a novel administration form comprising an acid-labile active compound, in particular an acid-labile proton pump inhibitor. The novel administration form is a suppository, in particular for rectal administration. Furthermore, the invention also relates to a process for the production of the administration form and preparations which can be used for the production of the administration form.

Prior art

[0002] Acid-labile proton pump inhibitors (H⁺/K⁺ ATPase inhibitors), in particular pyridin-2-ylmethylsulfanyl-1H-benzimidazoles, such as are disclosed, for example, in EP-A-0 005 129, EP-A-0 166 287, EP-A-0 174726 and EP-A-0 268 956, are of great importance on account of their H⁺/K⁺ ATPase-inhibiting action in the therapy of diseases which result from increased gastric acid secretion. Examples of already commercially available active compounds from this group are 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfanyl]-1H-benzimidazole (INN: omeprazole), 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfanyl]-1H-benzimidazole (INN: pantoprazole), 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulfanyl]-1H-benzimidazole (INN: lansoprazole) and 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfanyl]-1H-benzimidazole (INN: rabeprazole).

[0003] Because of their strong tendency to decompose in a neutral and, in particular, acidic environment, strongly colored decomposition products being formed, it is necessary to protect the active compounds in pharmaceutical administration forms from the action of acids and moisture and destruction by undesired interaction with pharmaceutical auxiliaries. For example, the strongly acid-labile pyridin-2-ylmethylsulfanyl-1H-benzimidazoles for oral administration forms are processed in the tablet core or in pellets in the form of their alkaline salts, for example as sodium salts, or together with alkaline substances.

[0004] The preparation of administration forms for acid-labile proton pump inhibitors for oral administration is described, for example, in EP-A-0 244 380, EP-A-0 519 365, EP-A-0 342 522, EP-A-0 277 741, WO 96/01623, WO 96/01624, WO 96/01625 and WO 97/25030.

[0005] In certain groups of patients, the oral administration of an active compound is not possible or is made difficult, for example in the case of patients having a hypersensitivity to taste impulses, in the case of difficulty in swallowing, after stomach operations or in patients in intensive care units. In these cases, the administration of an active compound can be effected by means of a suppository.

[0006] EP-0 645 140 describes compositions for rectal administration in which pyridin-2-ylmethylsulfanyl-1H-benzimidazoles and salts of fatty acids having 6-20 C atoms are present mixed in a base for rectal administration.

[0007] In WO 97/34580, a suppository for acid-labile active compounds is described which, in addition to the active compound, contains poloxamer and hydrophilic natural polymers as auxiliaries.

[0008] EP-0 444 625 discloses omeprazole compositions for rectal administration, which contain omeprazole as an active compound, a mixture of polyethylene glycols or a mixture of hard fat and sodium lauryl sulfate as well as a soluble basic amino acid.

[0009] WO98/52564 is related to a pharmaceutical composition which is a solid pellet comprising an inert core, a benzimidazole in or on the core, a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and an enteric coating around the moisture resistant coating. As hydrophobic material inter alia cetyl alcohol and polyalkylsiloxane are mentioned.

Description of the invention

[0010] It is an object of the present invention to provide a novel, stable suppository form for acid-labile active compounds.

[0011] It has now surprisingly been found that this object can be achieved by a suppository which comprises a plurality of individual active compound units, the acid-labile active compound in the individual active compound units being surrounded by a mixture of at least one sterol and at least one polymer.

[0012] The subject of the invention is a suppository for acid-labile active compounds, comprising at least one pharmaceutical auxiliary and a plurality of individual active compound units, wherein the acid-labile active compound in the individual active compound units is surrounded by a mixture of at least one sterol and at least one polymer.

[0013] A preferred subject of the invention is a suppository for acid-labile active compounds, comprising at least one pharmaceutical auxiliary and a plurality of individual active compound units, wherein the acid-labile active compound in the individual active compound units is surrounded by a mixture of at least one sterol and at least one polymer.

[0014] Further subjects follow from the patent claims.

[0015] The plurality of individual active compound units in the sense of the invention is a plurality of individual units (multiple individual units) in which at least one active compound particle is present surrounded by a mixture of at least one sterol and at least one polymer.

[0016] Further subject of the invention is an active compound unit comprising an acid-labile active compound, wherein the acid-labile active compound is surrounded by a mixture of at least one sterol and at least

one polymer.

[0017] The particle size of the individual units is advantageously less than 200 μm , in particular less than 100 μm . Preferably, the particle size is in the range from 2 μm to 50 μm , particularly preferably in the range from 4 μm to 20 μm .

[0018] Acid-labile active compounds in the sense of the present invention are, in particular, acid-labile proton pump inhibitors.

[0019] Acid-labile proton pump inhibitors (H^+/K^+ ATPase inhibitors) which may be mentioned in the sense of the present invention are, in particular, substituted pyridin-2-ylmethylsulfanyl-1H-benzimidazoles, such as are disclosed, for example, in EP-A-0 005 129, EP-A-0 166 287, EP-A-0 174 726, EP-A-0 184 322, EP-A-0 261 478 and EP-A-0 268 956. Preferably, mention may be made here of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfanyl]-1H-benzimidazole (INN: omeprazole), 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfanyl]-1H-benzimidazole (INN: pantoprazole), 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulfanyl]-1H-benzimidazole (INN: lansoprazole) and 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfanyl]-1H-benzimidazole (INN: rabeprazole).

[0020] Further acid-labile proton pump inhibitors, for example substituted phenylmethylsulfanyl-1H-benzimidazoles, cycloheptapyridin-9-ylsulfanyl-1H-benzimidazoles or pyridin-2-ylmethylsulfanylthienoimidazoles are disclosed in DE-A-35 31 487, EP-A-0 434 999 or EP-A-0 234 485. Mention may be made by way of example of 2-[2-(N-isobutyl-N-methylamino)benzylsulfanyl]benzimidazole (INN: leminoprazole) and 2-(4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ylsulfanyl)-1H-benzimidazole (INN: nepaprazole).

[0021] The acid-labile proton pump inhibitors are chiral compounds. The term acid-labile proton pump inhibitor also includes the pure enantiomers of the acid-labile proton pump inhibitors and their mixtures in any mixing ratio including the racemates. Enantiomerically pure acid-labile proton pump inhibitors are disclosed, for example, in WO 92/08716. Esomeprazole may be mentioned by way of example.

[0022] The acid-labile proton pump inhibitors are present here as such or preferably in the form of their salts with bases. Examples of salts with bases which may be mentioned are sodium, potassium, magnesium or calcium salts. If desired, the salts of the acid-labile proton pump inhibitors with bases can also be present in hydrate form. Such a hydrate of the salt of an acid-labile proton pump inhibitor with a base is disclosed, for example, in WO 91/19710.

[0023] Particularly preferred acid-labile proton pump inhibitors which may be mentioned are pantoprazole sodium and pantoprazole sodium sesquihydrate (= pantoprazole sodium $\times 1.5 \text{H}_2\text{O}$).

[0024] The sterol is preferably a phytosterol or a zoosterol. Phytosterols which may be mentioned by way of example are ergosterol, stigmasterol, sitosterol, brassi-

casterol and campesterol. Zoosterols which may be mentioned by way of example are cholesterol and lanosterol. If desired, mixtures of sterols can also be present.

[0025] The polymer is preferably a polymer having nonacidic groups. Polymers which may be mentioned by way of example are polyvidone (e.g. Kollidon 17, 30 and 90 from BASF), vinylpyrrolidone/vinyl acetate copolymer and polyvinyl acetate. Cellulose ethers such as, for example, methylcellulose, ethylcellulose (Ethocel) and hydroxypropylmethylcellulose and cellulose esters (e.g. cellulose acetate phthalate) may furthermore be mentioned. If desired, mixtures of polymers can also be present.

[0026] The amount (in % by weight) of active compound in the individual active compound unit is advantageously 1-90%. In case of units in which at least one active compound particle is present, surrounded by a mixture of at least one sterol and at least one polymer the amounts of sterol and of polymer are in each case advantageously 5-80%. Preferably, the amount of active compound is 10-50%, the amount of sterol is 10-40% and the amount of polymer is 10-50%.

[0027] It is possible for the person skilled in the art, on account of his/her expert knowledge, to select the best suited sterols and polymers depending on the active compound.

[0028] The individual active compound units can be prepared, for example, by spray-congealing (spray-solidification) or preferably by spray-drying. Preferably spray-drying is used for the preparation of individual active compound units in which the active compound is surrounded by a mixture of at least one sterol and at least one polymer. Spray-drying takes place from a suitable solvent. Suitable solvents for the spray-drying are preferably those in which the sterol and the polymer are soluble, while the active compound is insoluble. Suitable solvents can also be solvent mixtures.

[0029] If an acid-labile proton pump inhibitor, in particular a substituted pyridin-2-ylmethylsulfanyl-1H-benzimidazole, is employed as the active compound, the suitable solvents are, for example, hydrocarbons, chlorinated hydrocarbons and ethyl acetate. Hydrocarbons which may be mentioned are, in particular, linear or branched alkanes or alternatively cycloalkanes. Examples of linear alkanes are pentane, hexane and heptane. Examples of branched alkanes which may be mentioned are 2-methylpentane and 3-methylpentane. Examples of cycloalkanes which may be mentioned are cyclohexane and cyclopentane. If desired, mixtures of the hydrocarbons such as, for example, petroleum ether can also be employed. As a chlorinated hydrocarbon, chloroform and preferably dichloromethane may be mentioned.

[0030] On account of his/her expert knowledge in the field of spray-drying and, if necessary, by means of customary tests, it is possible for the person skilled in the art, depending on the active compound employed, to select the best suited sterols, polymers and solvents.

[0031] For spray-drying, the sterol and the polymer are dissolved in the suitable solvent and the active compound is suspended therein. If desired, the active compound can also be suspended first and the sterol and polymer then dissolved. The suspension obtained is then sprayed in a spray-dryer.

[0032] Spray-drying is carried out in a manner known per se. A detailed presentation of this technique is found in K. Masters, *Spray Drying Handbook*, 5th edition 1991, and J. Broadhead, S. K. Edmond Ronan, C. T. Rhodes, *The Spray Drying of Pharmaceuticals*, Drug Dev. Ind. Pharm. 18, 1169 (1992). The principle of spray-drying consists in breaking down a solution or suspension of the product to be dried into fine droplets and drying it using a hot stream of gas. The solid component remaining after evaporation of the solvent is separated off from the stream of gas by means of a cyclone and/or by a filter unit and collected.

[0033] Possible drying gases are, in particular, air and preferably nitrogen. The gas inlet temperature depends on the solvent.

[0034] Further subject of the invention is a preparation comprising an acid-labile active compound, at least one sterol and at least one polymer obtainable by spray-drying of a suspension of the acid-labile active compound in a solution of the sterol and the polymer in a suitable solvent.

[0035] Spray-congealing is carried out in a manner known per se. A detailed presentation of this technique is found for example in P.B. Deasy, *Microencapsulation and Related Drug Process* (1984).

[0036] The particle size of the active compound used in the spray-drying or spray-congealing process is advantageously less than 100 µm preferably less than 40 µm. Preferably, the particle size is in the range from 1-20 µm, particularly preferably in the range from 3-15 µm. Such particle size of the active compound for example can be achieved by milling the active compound in a suitable mill.

[0037] The individual active compound units, subsequently also designated as preparations, can then serve as a base for the production of the suppositories according to the invention.

[0038] Preferred suppositories which may be mentioned in this case are those which are suitable for rectal administration. The suppositories according to the invention are in this case prepared in a manner known to the person skilled in the art. For example, a suitable suppository base is fused and a preparation according to the invention is suspended therein. The suspension obtained is then brought into a form customary for suppositories. In particular, the suspension is cast to give a suppository shape suitable for rectal administration. Suitable suppository bases which may be mentioned are, for example, the hard fats customarily used for the production of rectal suppositories (subsequently also designated as *Adeps solidus* or *Adeps neutralis*). Hard fats are mixtures of mono-, di- and triglycerides which are ob-

tained by esterification of fatty acids (European Pharmacopeia, 3rd edition 1997, Deutscher Apotheker Verlag Stuttgart, p. 1022; The United States Pharmacopeia, USP23, NF18). Such hard fats are commercially available, for example, under the name Witepsol® (e.g. Witepsol® H12 or Witepsol® W31). If desired, further pharmaceutically acceptable auxiliaries, such as, for example, stabilizers, consistency-improving additives or auxiliaries which bring about a uniform distribution of the active compound in the suppository base, can be added.

[0039] The suppositories according to the invention contain the acid-labile active compound in a dose customary for the treatment of the appropriate disorder. The suppositories according to the invention comprising acid-labile proton pump inhibitors are suitable for the treatment and prevention of all diseases for the treatment or prevention of which pyridin-2ylmethylsulfanyl-1H-benzimidazoles are employed. In particular the suppositories according to the invention can be employed in the treatment of diseases of the stomach. Thus, the suppositories according to the invention contain between 1 and 500 mg, preferably between 5 and 60 mg, of an acid-labile proton pump inhibitor. Examples which may be mentioned are suppositories which contain 10, 20, 40 or 50 mg of pantoprazole sodium sesquihydrate. The daily dose (e.g. 40 mg of active compound) can in this case be administered in the form of a single administration or in several administrations using the suppositories according to the invention.

[0040] The suppositories comprising acid labile compounds according to the invention can also be combined with other active compounds, either in fixed or in free combination. Fixed combination in this connection relates to an administration form wherein all active compounds are present in a single dosage unit. Free combination in this connection relates to an administration form, wherein the active compounds are present in separated dosage units. In connection with suppositories comprising acid-labile proton pump inhibitors a combination with antimicrobially active compounds or NSAIDs (non steroidal anti inflammatory drugs) may be mentioned. Particularly mention may be made of a combination with antimicrobially active compounds which can be used in the control of *Helicobacter pylori* (*H. pylori*).

[0041] Examples of suitable antimicrobially-active ingredients (active against *Helicobacter pylori*) are enumerated in European Patent Application EP-A-282131. These active ingredients include, for example, bismuth salts (such as bismuth subcitrate or bismuth subsalicylate), sulfonamides, nitrofurans (such as nitrofurazone, nitrofurantoin or furazolidone), metronidazole, tinidazole, nimorazole or antibiotics. Examples of antibiotics which may be mentioned in this connection are, arranged according to particular classes of active ingredient: aminoglycosides, such as gentamicin, neomycin, kanamycin, amikacin or streptomycin; macrolides, such as erythromycin, azithromycin, clarithromycin, clindamycin or rifampicin; penicillins, such as penicillin G,

penicillin V, ampicillin, mezlocillin or amoxicillin; polypeptides, such as bacitracin or polymyxin; tetracyclines, such as tetracycline, chlorotetracycline, oxytetracycline, minocycline or doxycycline; carbapenems, such as imipenem, loracarbef, meropenem or panipenem; cephalosporins, such as cefalexin, cefoxitin, cefuroxime axetil, cefotaxime, cefpodoxime proxetil, cefaclor, cefadroxil or cephalothin; gyrase inhibitors, such as ciprofloxacin, norfloxacin, ofloxacin or pefloxacin; or other different antibiotics, such as chloramphenicol. Particularly worthy of mention in this connection is also the combination of a plurality of antimicrobially-active ingredients, for example the combination of a bismuth salt and/or tetracycline with metronidazole, or the combination of amoxicillin or clarithromycin with metronidazole and amoxicillin with clarithromycin.

[0042] Particularly worthy of mention in this connection is also administration of a proton pump inhibitor together with a plurality of antimicrobially-active ingredients, for example with the combination of a bismuth salt and/or tetracycline with metronidazole or with the combination of amoxicillin or clarithromycin or with metronidazole.

[0043] The preparation of suppositories according to the invention is described by way of example below. The examples below illustrate the invention in greater detail without restricting it.

Production of the preparations by spray-drying

Example 1

[0044] 7.0 g of cholesterol and 5.0 g of Ethocel are dissolved in 100 ml of dichloromethane. 5.0 g of pantoprazole sodium sesquihydrate are suspended in the solution. The suspension is spray-dried in a laboratory spray-dryer (Büchi Mini Spray Dryer B191). Spray conditions: drying gas nitrogen, inlet temperature 51°C; pump output 10%. A white, free-flowing powder is obtained.

Example 2

[0045] 5.0 g of cholesterol and 5.0 g of Kollidon 17 are dissolved in 80 ml of dichloromethane. 5.0 g of omeprazole magnesium are suspended in the solution. The suspension is spray-dried in a laboratory spray-dryer (Büchi Mini Spray Dryer B191). Spray conditions: drying gas nitrogen, inlet temperature 51°C; pump output 10%. A white, free-flowing powder is obtained.

Example 3

[0046] 5.0 g of cholesterol and 8.0 g of polyvidone 17 PF are dissolved in 60 ml of dichloromethane. 5.0 g of pantoprazole sodium sesquihydrate are suspended in the solution. The suspension is spray-dried in a laboratory spray-dryer (Büchi Mini Spray Dryer B191). Spray

conditions: drying gas nitrogen, inlet temperature 52°C; pump output 12%. A white, free-flowing powder is obtained.

Example 4

[0047] 5.0 g of cholesterol and 8.0 g of polyvidone 17 PF and 2.0 g of ethylcellulose are dissolved in 60 ml of dichloromethane. 5.0 g of pantoprazole sodium sesquihydrate are suspended in the solution. The suspension is spray-dried in a laboratory spray-dryer (Büchi Mini Spray Dryer B191). Spray conditions: drying gas nitrogen, inlet temperature 52°C; pump output 12%. A white, free-flowing powder is obtained.

Example 5

[0048] 5.0 g of β -sitosterol, 8.0 g of polyvidone 17 PF and 1.0 g of ethylcellulose are dissolved in 60 ml of dichloromethane. 5.0 g of pantoprazole sodium sesquihydrate are suspended in the solution. The suspension is spray-dried in a laboratory spray-dryer (Büchi Mini Spray Dryer B191). Spray conditions: drying gas nitrogen, inlet temperature 52°C; pump output 12%. A white, free-flowing powder is obtained.

[0049] The preparations obtained according to Examples 1 to 5 have a particle size in the range 10-40 μm . By variation of the spraying conditions, it is possible, for example, to obtain larger or smaller particles.

Preparation of the suppositories

Example A

[0050] 194.7 g of suppository base (Adeps solidus/neutralis) are fused to give a clear mass at 40-45°C. After cooling the mass to 39-40°C, the preparation obtained in Example 1 (15.3 g) is introduced homogeneously using a stirrer. The suspension obtained is cooled to 37-38°C and cast into suppositories of 2.1 g each.

Example B

[0051] 193.8 g of suppository base (Adeps solidus/neutralis) are fused to give a clear mass at 40-45°C. After cooling the mass to 39-40°C, the preparation obtained in Example 3 (16.2 g) is introduced homogeneously using a stirrer. The suspension obtained is cooled to 37-38°C and cast into suppositories of 2.1 g each.

Example C

[0052] 192.0 g of suppository base (Adeps solidus/neutralis) are fused to give a clear mass at 40-45°C. After cooling the mass to 39-40°C, the preparation obtained in Example 4 (18.0 g) is introduced homogeneously using a stirrer. The suspension obtained is cooled to 37-38°C and cast into suppositories of 2.1 g each.

Example D

[0053] 192.9 g of suppository base (Adeps solidus/neutralis) are fused to give a clear mass at 40-45°C. After cooling the mass to 39-40°C, the preparation obtained in Example 5 (17.1 g) is introduced homogeneously using a stirrer. The suspension obtained is cooled to 37-38°C and cast into suppositories of 2.1 g each.

[0054] The suppositories obtained according to Examples A to D in each case contain 45.6 mg of pantoprazole sodium sesquihydrate.

Stability of the suppositories

[0055] Samples of the suppositories obtained according to Examples A, B, C and D were stored at 30°C. After storage for 4 weeks, the suppositories were unchanged. No discoloration was detected. Suppositories in which the active compound was incorporated directly showed a black discoloration after storage for 4 weeks under identical conditions.

Claims

1. A suppository for acid-labile active compounds wherein the acid labile compound is an acid-labile proton pump inhibitor, a salt of an acid-labile proton pump inhibitor with a base or a hydrate of a salt of an acid-labile proton pump inhibitor with a base comprising at least one pharmaceutical auxiliary and a plurality of individual active compound units, wherein in each individual active compound unit the acid-labile active compound is surrounded by a mixture of at least one sterol and at least one polymer.
2. The suppository as claimed in claim 1, wherein the amount (in % by weight) of acid-labile active compound in the individual active compound unit is from 10 to 50%, the amount of sterol is from 10 to 40% and the amount of polymer is from 10 to 50%.
3. The suppository as claimed in claim 1, wherein the acid-labile proton pump inhibitor is pantoprazole, esomeprazole, omeprazole, lansoprazole or rabeprazole.
4. The suppository as claimed in claim 1, wherein the acid-labile proton pump inhibitor is pantoprazole sodium sesquihydrate.
5. The suppository as claimed in claim 1, wherein the sterol is cholesterol; lanosterol, ergosterol, stigmasterol, sitosterol, brassicasterol, campesterol or mixtures thereof.
6. The suppository as claimed in claim 1, wherein the polymer is polyvidone, vinylpyrrolidone/vinyl ace-

tate copolymer, polyvinyl acetate, methylcellulose, ethylcellulose, hydroxypropylcellulose, cellulose ester or mixtures thereof.

7. The suppository as claimed in claim 1, wherein the pharmaceutical auxiliary is hard fat (Adeps neutralis or Adeps solidus).
8. The suppository as claimed in claim 1, wherein the individual active compound units have a particle size less than 200 µm.
9. The suppository as claimed in claim 1, wherein the individual active compound units have a particle size less than 100 µm.
10. The suppository as claimed in claim 1, wherein the individual active compound units have a particle size in the range from 4-20 µm.
11. A process for the production of a suppository as claimed in claim 1, wherein the individual active compound units are introduced into a suitable suppository base and brought into a form suitable for the administration of suppositories.
12. A process for the production of a suppository as claimed in claim 1, which comprises dissolving at least one sterol and at least one polymer in a suitable solvent, suspending the acid-labile proton pump inhibitor therein, spray-drying the obtained suspension and introducing the individual active compound units produced into a suitable suppository base which is brought into a form suitable for the administration of suppositories.
13. Suppository obtainable by a process according to claim 12.
14. Suppository according to claim 1 comprising an acid labile proton pump inhibitor, at least one sterol and at least one polymer obtainable by spray-drying of a suspension of the acid-labile active compound in a solution of the sterol and the polymer in a suitable solvent.

Patentansprüche

1. Suppositorium für säurelabile Wirkstoffe, wobei es sich bei der säurelabilen Verbindung um einen säurelabilen Protonenpumpenhemmer, um ein Salz eines säurelabilen Protonenpumpenhemmers mit einer Base oder um ein Hydrat eines Salzes eines säurelabilen Protonenpumpenhemmers mit einer Base handelt, enthaltend wenigstens einen pharmazeutischen Hilfsstoff und mehrfach individuelle Wirkstoff-Einheiten, **dadurch gekennzeichnet**,

- daß** der säurelabile Wirkstoff in den individuellen Wirkstoff-Einheiten von einer Mischung aus wenigstens einem Sterol und wenigstens einem Polymer umhüllt wird.
2. Suppositorium nach Anspruch 1, **dadurch gekennzeichnet, daß** die Menge (in Gew.-%) an säurelabilem Wirkstoff in den individuellen Wirkstoff-Einheiten von 10 bis 50%, die Menge eines Sterol von 10 bis 40% und die Menge an Polymer von 10 bis 50% beträgt.
 3. Suppositorium nach Anspruch 1, **dadurch gekennzeichnet, daß** es sich bei dem säurelabilen Protonenpumpenhemmer um Pantoprazol, Esomeprazol, Omeprazol, Lansoprazol oder Rabeprazol handelt.
 4. Suppositorium nach Anspruch 1, **dadurch gekennzeichnet, daß** es sich bei dem säurelabilen Protonenpumpenhemmer um Pantoprazol-Natrium-Sesquihydrat handelt.
 5. Suppositorium nach Anspruch 1, **dadurch gekennzeichnet, daß** es sich bei dem Sterol um Cholesterol, Lanosterol, Ergosterol, Stigmasterol, Sitosterol, Brassicasterol, Campesterol oder Mischungen davon handelt.
 6. Suppositorium nach Anspruch 1, **dadurch gekennzeichnet, daß** es sich bei dem Polymer um Polyvidon, Vinylpyrrolidon/Vinylacetatcopolymer, Polyvinyl-acetat, Methylcellulose, Ethylcellulose, Hydroxypropylcellulose, Celluloseester oder Mischungen davon handelt.
 7. Suppositorium nach Anspruch 1, **dadurch gekennzeichnet, daß** es sich bei dem pharmazeutischen Hilfsstoff um hartes Fett (Adeps neutralis oder Adeps solidus) handelt.
 8. Suppositorium nach Anspruch 1, **dadurch gekennzeichnet, daß** die individuellen Wirkstoff-Einheiten eine Teilchengröße von unter 200 µm aufweisen.
 9. Suppositorium nach Anspruch 1, **dadurch gekennzeichnet, daß** die individuellen Wirkstoff-Einheiten eine Teilchengröße von unter 100 µm aufweisen.
 10. Suppositorium nach Anspruch 1, **dadurch gekennzeichnet, daß** die individuellen Wirkstoff-Einheiten eine Teilchengröße im Bereich von 4-20 µm haben.
 11. Verfahren zur Herstellung eines Suppositoriums nach Anspruch 1, **dadurch gekennzeichnet, daß** die individuellen Wirkstoff-Einheiten in einen geeigneten Suppositoriengrundstoff eingearbeitet und in eine für die Verabreichung von Suppositorien ge-

eignete Form gebracht werden.

12. Verfahren zur Herstellung eines Suppositoriums nach Anspruch 1, bei dem man wenigstens ein Sterol und wenigstens ein Polymer in einem geeigneten Lösungsmittel löst, den säurelabilen Protonenpumpenhemmer darin suspendiert, die so erhaltene Suspension sprühtrocknet und die so hergestellten individuellen Wirkstoff-Einheiten in einen geeigneten Suppositoriengrundstoff einarbeitet, der in eine für die Verabreichung von Suppositorien geeignete Form gebracht wird.
13. Suppositorium, erhältlich durch ein Verfahren nach Anspruch 12.
14. Suppositorium nach Anspruch 1, enthaltend einen säurelabilen Protonenpumpenhemmer, wenigstens ein Sterol und wenigstens ein Polymer, erhältlich durch Sprühtrocknung einer Suspension des säurelabilen Wirkstoffs in einer Lösung des Sterols und des Polymers in einem geeigneten Lösungsmittel.

25 Revendications

1. Suppositoire pour composés actifs acidolabiles dans lequel le composé acidolabile est un inhibiteur acidolabile de pompe à protons, un sel d'un inhibiteur acidolabile de pompe à protons avec une base ou un hydrate d'un sel d'un inhibiteur acidolabile de pompe à protons avec une base comprenant au moins un auxiliaire pharmaceutique et une pluralité d'unités individuelles de composé actif, dans lequel, dans chaque unité individuelle de composé actif, le composé actif acidolabile est entouré d'un mélange d'au moins un stérol et d'au moins un polymère.
2. Suppositoire selon la revendication 1, dans lequel la quantité (en % en poids) du composé actif acidolabile dans l'unité individuelle de composé actif est de 10 à 50%, la quantité de stérol est de 10 à 40% et la quantité de polymère est de 10 à 50%.
3. Suppositoire selon la revendication 1, dans lequel l'inhibiteur acidolabile de pompe à protons est le pantoprazole, l'esomeprazole, l'omeprazole, le lansoprazole ou le rabeprazole.
4. Suppositoire selon la revendication 1, dans lequel l'inhibiteur acidolabile de pompe à protons est le sesquihydrate de sodium de pantoprazole.
5. Suppositoire selon la revendication 1, dans lequel le stérol est le cholestérol, le lanostérol, l'ergostérol, le stigmasterol, le sitostérol, le brassicastérol, le campesterol ou des mélanges de ceux-ci.

6. Suppositoire selon la revendication 1, dans lequel le polymère est une polyvidone, un copolymère de vinylpyrrolidone et acétate de vinyle, un acétate de polyvinyle, une méthylcellulose, une éthylcellulose, une hydroxypropylcellulose, un ester de cellulose ou des mélanges de ceux-ci. 5
7. Suppositoire selon la revendication 1, dans lequel l'auxiliaire pharmaceutique est une matière grasse dure (*Adeps neutralis* ou *Adeps solidus*). 10
8. Suppositoire selon la revendication 1, dans lequel les unités individuelles de composé actif ont une taille de particule inférieure à 200 µm. 15
9. Suppositoire selon la revendication 1, dans lequel les unités individuelles de composé actif ont une taille de particule inférieure à 100 µm.
10. Suppositoire selon la revendication 1, dans lequel les unités individuelles de composé actif ont une taille de particule de 4 à 20 µm. 20
11. Procédé pour la production d'un suppositoire selon la revendication 1, dans lequel les unités individuelles de composé actif sont introduites dans une base de suppositoire appropriée et mises sous une forme appropriée à l'administration de suppositoires. 25
12. Procédé pour la production d'un suppositoire selon la revendication 1, qui comprend la dissolution d'au moins un stérol et d'au moins un polymère dans un solvant approprié, la mise en suspension de l'inhibiteur acidolabile de pompe à protons dans celui-ci, le séchage par atomisation de la suspension obtenue et l'introduction des unités individuelles de composé actif produites dans une base de suppositoire appropriée qui est mise sous une forme appropriée à l'administration de suppositoires. 30
35
40
13. Suppositoire pouvant être obtenu par un procédé selon la revendication 12.
14. Suppositoire selon la revendication 1 contenant un inhibiteur acidolabile de pompe à protons, au moins un stérol et au moins un polymère, pouvant être obtenu par séchage par atomisation d'une suspension du composé actif acidolabile dans une solution du stérol et du polymère dans un solvant approprié. 45
50

55